With growth in percutaneous fixes for the valve, surgeons at STS 2025 called for innovation, team-based care, and more data.

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Looking at the REVIVED-BCIS2 results, Divaka Perera and C. Michael Gibson discuss the relationship between myocardial viability, PCI, and outcomes.

This small but meaningful change seen in California may add up to a generational impact on consumption, but only time will tell.

The Medicare data contradict results from the TCW randomized trial but better represent real-world practice, say authors.